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61:1906–13.Regarding the Effect
of Dabigatran Plasma
ConcentrationsThe paper by Reilly et al. (1) suggested that up to 20% of patients
using the 110 and 150 mg twice daily dosing will fall outside
of the optimal concentration range of 35 to 300 ng/ml. Recently
unsealed court documents reveal internal pharmaceutical corre-
spondence that suppressed important data regarding dabigatran
therapy for patients with atrial ﬁbrillation (2,3). Corporate e-mails
suggest that the range may be narrower (3). These data were
removed from the ﬁnal paper by Reilly et al. (1) to avoid losing the
marketing advantage of being a monitor-free anticoagulant (4,5).
Given that up to 20% of patients will fall out of range and be at
risk for irreversible major bleeding or inadequate anticoagulation,
one wonders how such an omission can be justiﬁed. Pharmaceutical
companies that prioritize proﬁt over patients damage their scientiﬁc
credibility. Perhaps pulling dabigatran from hospital formularies
will send a message that clinicians will not be complicit in un-
dermining the public trust.*Rama B. Rao, MD
*Division of Emergency Medicine
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New York Presbyterian Hospital
Weill Cornell Medical College
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Concentrations
We would like to respond to Dr. Rao’s questions concerning our
paper (1). First, it is incorrect to state that any data on dabigatran and
plasma levels were suppressed. This information has been submitted
to all regulatory authorities as part of the original registration process
of dabigatran etexilate for reduction of stroke in patients with atrial
ﬁbrillation. These data have also been in the public domain since the
U.S. Food and Drug Administration (FDA) Advisory Committee
meeting in September 2010, before marketing approval (2).
Our paper, which investigated the exposure–response relation-
ship, documents plasma concentration as one factor affecting clinical
outcomes (1). Whether we could specify and defend a single
optimal concentration range for all patients was the subject of
extensive discussions among the coauthors. We ultimately came to
the conclusion that there is no single range that ﬁts all patients,
because individual patient demographics (e.g., age, renal function,
and prior stroke) are at least as important as the plasma concen-
trations in assessing beneﬁt–risk and confound the association
between drug levels and outcomes. Even with the high plasma
concentrations of dabigatran observed in patients with renal
dysfunction, the FDA has concluded there is a positive beneﬁt–
risk balance for patients (3). Further, RE-LY (Randomized Eval-
uation of Long-Term Anticoagulation Therapy) is the only trial of
a new oral anticoagulant that has published extensive data regarding
blood concentrations. It is likely that other anticoagulants will also
exhibit variability in blood concentrations.
Although it may appear attractive to monitor concentrations and
adjust dosing to improve outcomes, given the complex interactions
between plasma concentrations, demographics, and outcomes, we
cannot make recommendations on how to do this. In fact, without
routine testing in the RE-LY trial, dabigatran produces a clear net
beneﬁt over warfarin. The safety compared with warfarin has also
been conﬁrmed in post-marketing analyses by the FDA (4).*Paul A. Reilly, PhD
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Guideline on the Assessment
of Cardiovascular RiskWe applaud the effort of the ACC/AHA Risk Assessment Work
Group to develop novel equations to estimate the risk of a ﬁrst hard
atherosclerotic cardiovascular event using data from broadly
representative cohorts of the U.S. population (1). However, we are
concerned that they may not adequately predict risk in patients
with inﬂammatory forms of arthritis, such as rheumatoid arthritis,
psoriatic arthritis, and ankylosing spondylitis. Considerable epide-
miological evidence supports the notion that inﬂammatory arthritis
is an independent risk factor for both myocardial infarction and
stroke (2–4). In addition, a recent assessment of the performance
of cardiovascular risk algorithms in an early rheumatoid arthritis
inception cohort demonstrated that the Framingham Global
Risk Score, SCORE, and the Reynolds Risk Score all under-
estimated 10-year risk (5).
Although it is brieﬂy mentioned in the 2013 Blood Cholesterol
Guideline (6), we want to highlight the increased risk of cardio-
vascular disease in those with inﬂammatory arthritis and emphasize
that until well-validated risk scores are developed for this popula-
tion, using those derived from the general population will likely
underestimate risk.*Bruce Andrus, MD, MS
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on the Assessment of
Cardiovascular RiskThe American College of Cardiology Foundation/American Heart
Association (ACCF/AHA) welcomes letters to inform its ongoing
work and encourages such correspondence about its guidelines.
Because the ACCF/AHA guideline development process is
rigorous and involves several layers of review by the writing com-
mittee, external peer reviewers, and participating organizations in
the document, it cannot respond to each issue raised after a guide-
line has been published. The information, however, is forwarded to
the Writing Committee chair and oversight Task Force for review.
If any issue is deemed by the ACCF/AHA to affect patient safety,
it will be considered immediately. Otherwise, the information will
be considered during the next update or revision of the guideline.The ACC Guidelines Committee
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